Nyxoah’s hypoglossal nerve stimulation system, Genio, met the co-primary endpoints at 12 months in the pivotal DREAM trial in ...

By meeting primary safety and efficacy endpoints, the study marks a significant step forward for targeted hypoglossal nerve stimulation as a viable treatment for moderate to severe OSA.